b'The first FDA-approved, in-office treatment for molluscumThe first FDA-approved, in-office treatment for molluscumPhotos are illustrative and not representativeof all patients.YCANTH Is Now Accessible to Patients at Your Photos are illustrative and not representativeTreatment Facility of all patients.YCANTH \x19 a proven first-line topical therapy for your patientsDMS Pharmaceutical Group, Inc and Cencora are accepting orders for YCANTH (cantharidin)1topical solution 0.7%. Call 1-877-788-1100 for additional information.Precise delivery directly to molluscum lesions2YCANTH \x19 a proven first-line topical therapy for your patients1Small applicator A coloring agent helps preventContains a bitteringConsistent formulationPrecise delivery directly to molluscum lesions agent to help deterof 0.7% (w/v) opening allows for Single-use multiple applications to the 2targeting of each lesion applicator same lesion ingestion cantharidinSmall applicatorA coloring agent helps preventContains a bitteringConsistent formulation opening allows forSingle-usemultiple applications to theagent to help deterof 0.7% (w/v) targeting of each lesion applicator same lesion ingestion cantharidinApplicator is not to scale.Adverse reactions were primarily mild to moderate local skin reactions at the application site, including vesiculation, pruritus, pain, discoloration, and erythema. 2Applicator is not to scale. YCANTH is covered by 90% of the top commercial health plans 3 *Adverse reactions were primarily mild to moderate local skin reactions at the application site, including vesiculation, pruritus, pain, discoloration, and erythema. 2INDICATION DRUG INTERACTIONS:YCANTH (cantharidin) topical sol NTH i .7% is indic d by 90% of the topdi ommercial healthte lans 3 *YCA ution, 0 s covere ated for theNo stu c es evaluating the drug in p raction potentialtopical treatment of molluscum contagiosum in adult and pediatric of cantharidin have been conducted.patients 2 years of age and older. INDICATION USRE IUGN S INPTEECRIAFCIC PTIOONPSU: LATIONS:DIM Proe gstnuadniceys : Tevhaelurae atinrge n tho ave drauigla ibnlte deraactta wioni tph uotesne otiaf YlCANTH in YCPAONTRH (TAcNanT SthaAriFdEinT) tY IopNicFal sORolMutAioTnI, 0ON.7% is indicated for theNtoOpiNcaTl RtrAeaINtmDeInCtA oTf ImOoNlluSs:cum contagiosum in adult and pediatricofr ecgannathnat wridoinm hean tveo e beveanl ucaotne fduocr a dted.r ug-associated risk of major C pNaotnieen. ts 2 years of age and older.birth defects, miscarriage or adverse maternal or fetal outcomes. p UiSvE Ien N SthatP sEyCstIeFmIC Pic exOpPoUsuLrAe TtoI OcaNnSth: aridin following topicalWARNINGS AND PRECAUTIONS: GIMPORTANT SAFETY INFORMATION Pdremginnaisntcrayt: Tiohn ies lre aowre n, mo avateranialal ublse de ias nta wot eitxh upesce oted tf Yo rCAeNsuTlH it in fetal n YCANTH is for topical use only. YCANTH is not for oral, mucosal, aCONTRAINDICATIONS: pregnant women to evaluate for a drug-associated risk of major exposure to the drug.Noonre o. phthalmic use. Life threatening or fatal toxicities can occur if birth defects, miscarriage or adverse maternal or fetal outcomes. YCANTH is administered orally. Avoid contact with the treatment LGaivcetant itohna: At svyostid aempicp elixcpatoisoun ore f Yto CcaAnNthTaH tridoinp ifcoall slowoliuntgio tn topo aicarl eas WAarReaN, iInNcGluS AdingN oD Pral cRonEtCacAt,U afTtIeOr tNreSa:tment. Ocular toxicity can occur wYCANTH is for topical use only. YCANTH is not for oral, mucosal,aditmh iinnisctrreaatsioen id rs lisk fowo, mr paotteernntail ual isne iges nstioot en bxy opecr otecd tulo rar eexsuplot isun fre teto al if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush thxep obsruerae to the do tal toxicities can occur ife stfeedingr cuhgi.ld.eyr eosp whtihtha lwmaict eurs feo. rL aifte l ethasret a1t5e nminingu oter sfa.Y LaVctEaRtiDonO: ASAvoGid aE: pplication of YCANTH topical solution to areas LoCcAaNl STkHin i sR aedamctiinoinsst:e Rreeda cotriaolnlys.aAtv tohiedacpopntliaccatt iwonit hsi tteh em tarye aotcmcuern,tOOirtah il inngcreesatisoend r ofis ck fanotr phaoritdeinn thiaal is nregseuslttieodn b iny o rer onalc fualialur erex, pbolissutere trino garcelau,d inincglu vdeisnigc uolraatli ocno,n ptraucrti,t aufst,e pra tirne, adtimsceonlot.r Oatciounla, ra tnodx iecrityyt hceamn ao.ccurwin aif vYoCidA aNpTpHlic caotimone sn iena cro enyteasc ta nwdi tmh uecyoessa. Il ft iYsCsuAeN, aTnHdgtoet hse ina ltehyyes, flush thned s breevaesrte dfeeadminagg e tcho tild.he gastrointestinal tract, coagulopathy, A seizures, and flaccid paralysis. eyes with water for at least 15 minutes. skin. If YCANTH contacts any unintended surface, or healthy skin, OVERDOSAGE:Lomcael dSikaitne lRye raecmtioovnes.:IRf esaecvteioren slo actal skin reactio the applicationnssoictec umr,a rye mococvuer,prior .im Please see Brief Summary of Prescribing Information onu ared,j abcleisntte rpiangge i oc tlhued irnegc voemsmicuelnadtieodn ,2 p4r uhroituurss,apfateinr,tdreisactomloernatt.ion, and erythema.Oral ingestion of cantharidin has resulted in renal failtn anled sasee sveere fe duall Pmargee tsco tribhine gg Iansftorrominatteiostn ainat Yl trCaActN, cToHaPgruolo.cpoamth. y, A r eyeesn a anfdte mr udcryoisnagl .t Aisvsuoeid,afinred,tfola hmeea lothr ys moking PYCvoAiNd TapHp ilsic falatimonm naebale, ev seizures, and flaccid paralysis. skeianr.lIef sYioCnA(sN) TdHur cinogn ttraecattsm aenny tu annindt aefntdeer da pspulrifcaacteio, no ru hnetial lrtehmy oskviend, . To report SUSPECTED ADVERSE REACTIONS, contact Verrica nimmediately remove. If severe local skin reactions occur, remove prior Plheaarsme asecee uBtriiceafl Ss uInmcm. aatr y1 -o8f7 P7r-eVscErRibRinICgA In (f1o-r8m7a7t-i8on3 7o-n7 4a2dj2a)c, eonrt page. PADtoV tEhRe SreEcoRmEmAeCnTdeIOd N24S h: ours after treatment.FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin The most common (incidence 1%) reactions are the following localPlease see full Prescribing Information at YCANTHPro.com. YCANTH is flammable, even after drying. Avoid fire, flame or smoking reactions are expected and should be reported if they are severe.skinne raera lcetsiioonn(ss )a dt uthrien ga ptrpelaictmateionntasnitde :a vfteesri caupplalticioatnio, pna uinn,t ipl rreumritouvse,d. To report SUSPECTED ADVERSE REACTIONS, contact Verrica scabbing, erythema, discoloration, application site dryness, edema, Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or References: 1. Centers for Disease Control and Prevention. Molluscum contagiosum: treatmentanDd eVEroRsSioEn . LREocAaCl sTkIiOn rNeSa:ctions at the application site wereoptions. Acces800-FDA-1088 or www.fda.gov/medwatch. Locsul skin A FDA at 1-sed March 4, 2024. https://www.cdc.gov/poxvirus/molluscum-contagioam/treatment.The most common (incidence 1%) reactions are the following localhtml 2. YCANTH (cantharidin) topical solution 0.7% Prescribing Information, Verrica Pharmaceuticals Inc.,observed in 97% of subjects treated with YCANTH during clinicalreactions are expected and should be reported if they are severe. srkiianls r. Teahcetisoe lnso acta l sthkei n rappealiccatitoionns a sirte ee: vxepseiccutelad ationnd r, pealiant,e pd truo trituhse ,2023.3. Data on file. Verrica Pharmaceuticals Inc.; 2024.tscabbing, erythema, discoloration, application site dryness, edema,Refer d on a revi enters for e top 50 heal rol and ns in th tion. Mo d State s. ontagiosum: treatmentanticipated blistering response of the skin to cantharidin.*Base ences: 1. C ew of thDisease Cont th plaPreven e Unite lluscumc 3and erosion. Local skin reactions at the application site wereoptions. Accessed March 4, 2024. https://www.cdc.gov/poxvirus/molluscum-contagiosum/treatment.observed in 97% of subjects treated with YCANTH during clinicalhtml 2. YCANTH (cantharidin) topical solution 0.7% Prescribing Information, Verrica Pharmaceuticals Inc.,trials. These local skin reactions are expected and related to the2023. 3. Data on file. Verrica Pharmaceuticals Inc.; 2024.Scan the QR code or visit3anticipated blistering response of the skin to cantharidin.*Based on a review of the top 50 health plans in the United States. YCANTHPro.com to learn moreScan the QR code or visit Patented: www.verrica.com/patentsYCANTHPro.com to learn moreYCANTH is a registered trademark of VerricaPharmaceuticals Inc.Copyright2024, Verrica PharmaceuticalsInc. All rights reserved. ( 11 /24)US-YCN-00207Patented: www.verrica.com/patentsYCANTH is a registered trademark of Verrica Pharmaceuticals Inc.Copyright2024, Verrica Pharmaceuticals Inc. All rights reserved. ( 11 /24)US-YCN-00207'